By vgreene, 15 April, 2020 Favipiravir vs Arbidol for COVID-19: A Randomized Controlled Trial; access medRxiv article
By vgreene, 15 April, 2020 Study considerations: non-comparative, retrospective, small sample size, varied dosing regimens, inconsistent monitoring of lab parameters, limited f/u
By vgreene, 15 April, 2020 CRP levels normalized in 11 pts; IL-6 levels were lower compared to pre-tx levels in 3 pts; 3 pts died; 2 pts had clinical dz progression
By vgreene, 15 April, 2020 Retrospective study; 15 hospitalized pts (mean age, 72y; 4 seriously ill, 7 critically ill) w/ confirmed COVID-19 treated w/ TCZ (doses ranged 80 mg to 600 mg per dose, 5 pts received >1 dose); 8 pts also received methylprednisolone
By vgreene, 15 April, 2020 Study considerations: randomized but open-label; delayed tx initiation from sx onset; viral kinetics showed possible lack of antiviral effect (LPV/r exposure at normal doses lower vs concentrations needed for anti-SARS-CoV-2 activity)
By vgreene, 15 April, 2020 A Pilot Study of Hydroxychloroquine in Treatment of Patients With Common Coronavirus Disease-19 (COVID-19)